A Nitric Oxide-Releasing Salbutamol Elicits Potent Relaxant and Anti-Inflammatory Activities

Lagente, Vincent; Naline, Emmanuel; Guénon, Isabelle; Corbel, M; Boichot, Elisabeth; Burgaud, Jean-Luc; Soldato, Piero Del; Advenier, C.

doi:10.1124/jpet.103.061739

Cited by 27 publications

(14 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The nil to moderate degree of cGMP-mediated bronchial dilation that is evidenced is consistent with the results of other investigators [15][16][17], emphasising the confounding effect of underlying pathology (such as endothelial dysfunction) and the modest contribution of cGMP-mediated dilation in airways. The presence of a systemic endothelial dysfunction suggests an impairment of NO-mediated relaxation in COPD.…”

Section: Bronchial Dysfunctionsupporting

confidence: 90%

Association of ex vivo vascular and bronchial dysfunctions in smokers

Oualha¹,

Boitiaux²,

Tadié³

et al. 2011

Pulmonary Pharmacology & Therapeutics

Self Cite

View full text Add to dashboard Cite

Word count: 204Background. It has recently been shown that systemic endothelial dysfunction is associated with airflow limitation in COPD. We conducted this ex vivo study to assess whether endothelial dysfunction of pulmonary arteries of former smokers was associated with modifications of airway functions. Conclusion. Endothelial dysfunction of pulmonary arteries is associated with increasedresting tone and impaired cGMP-mediated dilation of airways in former smokers, suggesting common underlying mechanisms of pulmonary arterial and bronchial dysfunctions.

show abstract

Section: Bronchial Dysfunctionsupporting

confidence: 90%

Association of ex vivo vascular and bronchial dysfunctions in smokers

Oualha¹,

Boitiaux²,

Tadié³

et al. 2011

Pulmonary Pharmacology & Therapeutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…NO-budesonide (TPI 1020) [65,66] was the first example of such a drug, but this drug was dropped from further development because of limited clinical efficacy. Another approach attempted to combine nitric oxide and salbutamol into a single molecule (NCX 950) to obtain both bronchodilator and antiinflammatory actions, which showed some promise pre-clinically [67] (table 1).…”

Section: Bifunctional Bronchodilator/anti-inflammatory Drugsmentioning

confidence: 99%

Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease

Page

Cazzola

2014

Eur Respir J

View full text Add to dashboard Cite

Over the last decade, there has been a steady increase in the use of fixed-dose combinations of drugs for the treatment of a range of diseases, including hypertension, cancer, AIDS, tuberculosis and other infectious diseases. It is now evident that patients with asthma or chronic obstructive pulmonary disease (COPD) can also benefit from the use of fixed-dose combinations, including combinations of a long-acting b 2 -agonist and an inhaled corticosteroid, and combinations of long-acting b 2 -agonists and long-acting muscarinic receptor antagonists. In fact, there are now a number of ''triple-inhaler'' fixed-dose combinations under development, with the first such triple combination having been approved in India. This use of combinations containing drugs with complementary pharmacological actions in the treatment of patients with asthma or COPD has also led to the discovery and development of drugs having two different primary pharmacological actions in the same molecule, which we have called ''bifunctional drugs''. In this review, we discuss the state of the art of these new bifunctional drugs as novel treatments for asthma and COPD that can be categorised as bifunctional bronchodilators, bifunctional bronchodilator/antiinflammatory drugs and bifunctional anti-inflammatory drugs. @ERSpublications Bifunctional drugs offer an exciting new approach to the treatment of asthma and COPD

show abstract

“…Ae ro soli zed sil de na fil cit ra te do se of 0.07 mg/ml was choosen similar to anot her study con duc ted with BALB/c mi ce. 12 Sil de na fil cit ra te was kindly do nated by Fa ko Drug In dustry (Is tan bul, Tur key). Alt ho ugh ne bu li zed sil de na fil cit ra te was not ava i lab le in the mar ket, it was pre pa red as done in Turkiye Klinikleri J Med Sci 2010;30 (2) a pre vi o us study.…”

Section: Study Drugsmentioning

confidence: 99%

Impact of Nebulized Sildenafil on Lung Histology in a Murine Model of Chronic Asthma

Karaman¹,

Ölmez²,

Babayiğit³

et al. 2010

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

A AB BS S T TR RA AC CT T O Ob b j je ec c t ti i v ve e: : Sil de na fil, which is used for the tre at ment of erec ti le dysfunc ti on, has be en shown to in hi bit inf lam ma ti on in an ani mal mo del of ast hma. We ai med to de ter mi ne the im pact of ne bu li zed sil de na fil on lung his to logy in a mu ri ne mo del of chro nic ast hma. M Ma at te er ri ia al l a an nd d M Me et t h ho od ds s: : Forty-two BALB/c mi ce we re di vi ded in to six gro ups; A, B, C, D, E, and the con trol group. All gro ups ex cept con trols we re sen si ti zed and chal len ged with oval bu min. Then, mi ce in Group A re ce i ved ne bu li zed sa li ne. Ne bu li zed sil de na fil cit ra te was administered to Gro up B, C, and D at con cen tra ti ons of 0.035 mg/ml, 0.07 mg/ml, and 0.105 mg/ml res pec ti vely, and ne bu li zed bu deso ni de was administered at a con cen tra ti on of 0.25 mg/ml to Gro up E for 15 mi nu tes on ce a day, for a we ek. Ani mals we re sac ri fi ced 24 ho urs af ter the last in ha la ti o nal ex po su re and the air way samp les we re eva lu a ted his to lo gi cally by light and elec tron mic ros co py. R Re e s su ul lt ts s: : All the his to lo gic para me ters of ast hma in Gro up B we re sig ni fi cantly ame li o ra ted when com pa red to the ones in Gro up A. In Gro ups C and D, all the pa ra me ters ex cept thick nes ses of su be pit he li al smo oth musc le la yers we re sig ni fi cantly im pro ved when com pa red to Gro up A. Thick nes ses of ba se ment mem bra ne, sube pit he li al smo oth musc le, and epit he li um we re sig ni fi cantly smaller in Gro up B than Gro up E. Thick nes ses of ba se ment mem bra ne and su be pit he li al smo oth musc le we re sig ni fi cantly smaller in Gro up C than Gro up E. Thick ness of su be pit he li al smo oth musc le was sig ni fi cantly smaller in Group D than Gro up E. C Co on nc c l lu u s si i o on n: : The res pon ses re gar ding im pro ve ment in ast hma pat ho logy we re fo und bet ter with all do ses of ne bu li zed sil de na fil than pla ce bo and even ne bu li zed ste ro id. K Ke ey y W Wo or rd ds s: : Sil de na fil; ast hma; mi ce, in bred BALB C Ö ÖZ ZE ET T A Am ma aç ç: : Erek til dis fonk si yo nun te da vi sin de kul la nı lan sil de na fi lin bir as tım hay van mo delin de inf la mas yo nu in hi be et ti ği gös te ril miş tir. Biz ilk kez bir kro nik as tım fa re mo de lin de akci ğer his to lo ji si üze ri ne ne bu li ze sil de na fi lin et ki si ni araş tır ma yı amaç la dık. G Ge er re eç ç v ve e Y Yö ön nt te em ml le er r: : Kırk iki BALB/c fa re al tı gru ba ay rıl dı; A, B, C, D, E ve kon trol gru bu. Kon trol ler dı şın da ki tüm fa re ler oval bu min ile du yar lı laş tı rıl dı ve pro va ke edil di. Da ha son ra Grup A' da ki fa re ler ne buli ze sa lin, Grup B, C ve D'de ki ler sı ra sı ile 0.035 mg/ml, 0.07 mg/ml ve 0.105 mg/ml kon san trasyon lar da ne bu li ze sil de na fil sit rat, Grup E' de ki fa re ler 0.25 mg/ml kon san tras yon da ne bu li ze bu de so ni di gün de 15 da ki ka ol mak üze re bir haf ta bo yun ca al dı....

show abstract

A Nitric Oxide-Releasing Salbutamol Elicits Potent Relaxant and Anti-Inflammatory Activities

Cited by 27 publications

References 34 publications

Association of ex vivo vascular and bronchial dysfunctions in smokers

Association of ex vivo vascular and bronchial dysfunctions in smokers

Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease

Impact of Nebulized Sildenafil on Lung Histology in a Murine Model of Chronic Asthma

Contact Info

Product

Resources

About